Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing
- 1 March 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (3), 1185-1193
- https://doi.org/10.1128/aac.01292-08
Abstract
Caspofungin is used for the treatment of acute invasive candidiasis and as salvage treatment for invasive aspergillosis. We report characteristics of isolates of Candida albicans and Aspergillus fumigatus detected in a patient with breakthrough infection complicating severe gastrointestinal surgery and evaluate the capability of susceptibility methods to identify candin resistance. The susceptibility of C. albicans to caspofungin and anidulafungin was investigated by Etest, microdilution (European Committee on Antibiotic Susceptibility Testing [EUCAST] and CLSI), disk diffusion, agar dilution, and FKS1 sequencing and in a mouse model. Tissue was examined by immunohistochemistry, PCR, and sequencing for the presence of A. fumigatus and resistance mutations. The MICs for the C. albicans isolate were as follows: >32 μg/ml caspofungin and 0.5 μg/ml anidulafungin by Etest, 2 μg/ml caspofungin and 0.125 μg/ml anidulafungin by EUCAST methods, and 1 μg/ml caspofungin and 0.5 μg/ml anidulafungin by CLSI methods. Sequencing of the FKS1 gene revealed a mutation leading to an S645P substitution. Caspofungin and anidulafungin failed to reduce kidney CFU counts in animals inoculated with this isolate ( P > 0.05 compared to untreated control animals), while both candins completely sterilized the kidneys in animals infected with a control isolate. Disk diffusion and agar dilution methods clearly separated the two isolates. Immunohistochemistry and sequencing confirmed the presence of A. fumigatus without FSK1 resistance mutations in liver and lung tissues. Breakthrough disseminated aspergillosis and candidiasis developed despite an absence of characteristic FKS1 resistance mutations in the Aspergillus isolates. EUCAST and CLSI methodology did not separate the candin-resistant clinical isolate from the sensitive control isolate as well as did the Etest and agar methods.Keywords
This publication has 50 references indexed in Scilit:
- Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive BreakpointsAntimicrobial Agents and Chemotherapy, 2009
- Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus : the Challenge of Azoles versus EchinocandinsAntimicrobial Agents and Chemotherapy, 2008
- Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- Aspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based IdentificationAntimicrobial Agents and Chemotherapy, 2008
- Effects of Serum on In Vitro Susceptibility Testing of EchinocandinsAntimicrobial Agents and Chemotherapy, 2007
- A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2007
- One year prospective survey of Candida bloodstream infections in ScotlandJournal of Medical Microbiology, 2007
- Resistance to echinocandin-class antifungal drugsDrug Resistance Updates, 2007
- Serum Differentially Alters the Antifungal Properties of Echinocandin DrugsAntimicrobial Agents and Chemotherapy, 2007
- Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin SusceptibilityAntimicrobial Agents and Chemotherapy, 2006